Articles By Jack Cush, MD
Western Diet Increased the Risk of Rheumatoid Arthritis
Liu and coworkers from Boston presented abstract #1213, with data from the NHS II Survey. They examined 93,859 women (without RA) and their dietary data from 1991 to 2011.
Read Article
Improving Cardiovascular Trends in Rheumatoid Arthritis
Myasoedova and colleagues from the Mayo Clinic have reported their new data that demonstrates improving cardiovascular (CV) mortality rates in current RA patients treated with modern drugs.
Read Article
Chondroitin Superior to Celecoxib in Knee OA Cartilage Loss
A study of 194 knee OA patients received either 1200 mg chondroitin sulfate or celecoxib 200 mg daily, and clinical and MRI outcomes were assessed at 1 and 2 years.
Read Article
2015 ACR RA Guidelines Released– Finally!
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
Read Article
Invokana Decreases Autoimmune Risk
In September, the FDA issued warnings that the dipeptidyl peptidase-4 (DPP4) inihibitor Invokana may cause a dose-dependant increased risk of bone fractures. This was based on a review of nin
Read Article
FDA Panel Advises Stronger Warnings on Fluoroquinolones
An FDA Advisory Panel reviewed the safety of fluoroquinolones and their use to treat sinus infections, urinary-tract infections and bronchitis.
Read Article
Tried-and-True or Something New?
While decades of drug development have improved treatment options, some of our older drugs are harder to improve upon. The same can be said for old movies and new movies, or classic literature and current best sellers. Which do you prefer or rely on?
Read Article
Knee OA (not Hand) is Associated with Higher Mortality in Women
"Doc....the pain is killing me." This oft heard patient complaint may be truer than you think.
Read Article
Biosimilars and the FDA
Biosimilars are in the news and will be prominently on parade at next week's ACR meeting in San Francisco. Biosimilars are similar to, but not the same as, innovator biologics.
Read Article
